President & Representative Director, Kaken Pharmaceutial Co., Ltd.
Other assets (est.): the sum of each year's after-tax income (pay + dividends in own name − estimated taxes and social insurance) and dividends retained by asset-management companies (less about 20% corporate tax), for the years we have data. Spending, real estate, donations and savings from earlier years are not reflected.
| Company | Held by | Shares | Stake | Price | Value | Dividends |
|---|---|---|---|---|---|---|
| Kaken Pharmaceutial Co., Ltd. 4521 · FY ending Mar 2026 · President & Representative Director |
Own name | 9,697 | — | ¥4,141 | ¥40.2M | ¥1.8M |